SCP
NBIX icon

Seizert Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History

Seizert Capital Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.7M Buy
277,337
+189,677
+216% +$28.1M 1.93% 22
2026
Q1 		$11.5M Buy
87,660
+16,990
+24% +$2.25M 0.53% 44
2025
Q4 		$10M Buy
70,670
+635
+0.9% +$92K 0.42% 47
2025
Q3 		$9.83M Buy
+70,035
New +$9.49M 0.43% 49

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Seizert Capital Partners's NBIX Position: Q2 2026 in Review

Seizert Capital Partners increased its Neurocrine Biosciences (NBIX) stake by 216% in Q2 2026, buying an estimated $28.1M and bringing the position to 277,337 shares worth $46.7M. The position accounts for 1.93% of the portfolio, ranked #22.

Seizert Capital Partners first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Seizert Capital Partners held 277,337 shares of Neurocrine Biosciences worth $46.7M as of Q2 2026.
  • Seizert Capital Partners bought 189,677 Neurocrine Biosciences shares in Q2 2026, an estimated $28.1M.
  • Neurocrine Biosciences made up 1.93% of Seizert Capital Partners's portfolio in Q2 2026, its #22 holding.
  • Seizert Capital Partners first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Seizert Capital Partners's 13F filing for Q2 2026, filed 5 Aug 2026.